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An observational surveillance study was conducted to monitor the 
safety and effectiveness of treatment with Digoxin Immune Fab 
(Ovine) (Digibind) in patients with digitalis intoxication. Before 
April 1986, a relatively limited number of patients received 
treatment with digoxin-specific Fab fragments through a multi-
center clinical trial. Beginning with commercial availability in 
July 1986, this study sought additional, voluntarily reported 
clinical data pertaining to treatment through a 3 week follow-up. 
The study included 717 adults who received Digoxin Immune 
Fab (Ovine). Most patients were :0:::70 years old and developed 
toxicity during maintenance dosing with digoxin. Fifty percent of 
patients were reported to have a complete response to treatment, 
24% a partial response and 12% no response. The response for 
14% of patients was not reported or reported as uncertain. Six 
Antibodies have been used to treat the injurious effects of 
natural toxins for many years. More recently. immunother-
apies have been developed to manage drug-induced toxicity 
(! ,2). In the case of life-threatening digitalis intoxication 
resulting from massive ingestion, antibody therapy has been 
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patients (0.8%, 95% confidence interval 0.3% to 1.8%) had an 
allergic reaction to digoxin-specific antibody fragments. Three of 
the six had a history of allergy to antibiotic drugs. Twenty patients 
(2.8 %, 95 % confidence interval 1.7% to 4.3 %) developed recru-
descent toxicity. Risk of recrudescent toxicity increased sixfold 
when <50% of the estimated dose of antibody was administered. 
A total of 215 patients experienced posttreatment adverse events. 
The events for 163 patients (76%) were judged to result from 
manifestations of underlying disease and thus considered unre-
lated to Fab treatment. 
Digoxin-specific antibody fragments were generally well toler-
ated and clinically effective in patients judged by treating physi-
cians to have potentially life-threatening digitalis intoxication. 
(J Am Coil CardioI1991;17:590-8) 
shown to be particularly valuable because clinical benefit 
from conventional therapies is limited (3). 
Digoxin-specific antibodies were first produced in 1967 (4) 
and initially used in quantitative assays of digoxin in human 
serum (5). Their therapeutic potential was subsequently 
demonstrated by successful prevention and reversal of the 
toxic effects of digitalis in rabbits and dogs (6.7). Antibody 
therapy appears to reverse toxicity by binding extracellular 
digoxin. resulting in a concentration gradient that permits 
the release and binding to high affinity Fab fragments of 
membrane-bound digoxin (8). 
Concerns regarding the potential for adverse immuno-
logic responses to whole exogenous antibody led to the 
development of affinity chromatographic techniques for iso-
lating purified digoxin-specific antibody fragments (9). The 
antibodies are harvested from the serum of hyperimmunized 
sheep. precipitated as a crude protein fraction with octanoic 
acid, digested with papain and purified on a ouabain-
sepharose affinity gel. Eluates containing digoxin-specific 
Fab fragments are dialyzed before blending, final formula-
tion and lyophilization. 
In baboons and rabbits the immunologic response to the 
purified Fab fragments was of lesser magnitude and later 
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onset than that produced by intact immunogammaglobulin 
(IgG) (10). In addition, the smaller Fab fragments (50,000 d) 
were more rapidly distributed and eliminated than IgG 
(150,000 d) (9). Digoxin-specific Fab fragments were also 
capable of reversing preexisting effects of digitalis in vitro 
and in vivo. Reversal of toxicity was more rapid with Fab 
fragments than with IgG fractions (I 1). The positive inotro-
pic effects of digoxin, as well as the toxic effects, were 
reversed (12). 
Clinical use of digoxin-specific Fab fragments to treat 
life-threatening digitalis toxicity was first reported in 1976 
(13). The clear clinical benefit in this and similar cases led to 
the initiation of a multicenter clinical trial to evaluate the 
safety and effectiveness of ovine digoxin-specific Fab frag-
ments in the treatment of advanced digitalis toxicity (14, 15). 
At the conclusion of this trial 150 patients had received 
treatment with digoxin-specific Fab fragments (16). Half of 
the patients treated had developed toxicity during mainte-
nance therapy with digoxin and most patients had a rapid 
response to antibody therapy. No allergic responses were 
detected. Two patients experienced recrudescent digitalis 
intoxication after response to an inadequate dose of digoxin-
specific Fab fragments. Neither of these patients had renal 
failure, which could be an important risk factor for recru-
descence. 
The product license for Digoxin Immune Fab (Ovine) 
(Digibind) (hereafter referred to as Fab) was granted by the 
Food and Drug Administration in April 1986. At that time 
there were few data available regarding the immunogenic 
potential of Fab in clinical use, the populations at highest 
risk for an allergic response or the immunogenic effects of 
readministering the antibody fragments for subsequent epi-
sodes of toxicity. Similarly, the circumstances in which Fab 
would be used outside of the clinical trial setting were 
unknown. 
We undertook a postmarketing surveillance study to 
further evaluate safety and effectiveness of treatment with 
Fab. The specific objectives of this study were to 1) quanti-
tate any risk of allergic response after initial and subsequent 
treatments with Fab, 2) identify any serious but infrequent 
adverse events that may not have been detected in the 
multicenter clinical trial, 3) assess clinical response or non-
response to treatment, and 4) characterize the patients and 
the nature of the toxicity treated with Fab. 
Methods 
Study protocol. This United States study was observa-
tional and relied on the voluntary participation of numerous 
hospital pharmacists, nurses and physicians. The participa-
tion of all United States hospitals was sought. To monitor as 
many treatments as possible per center, hospital pharmacies 
were asked to initiate data collection at their institution. 
When Fab was requested from the pharmacy, pharmacists 
completed the dispensing section of each form, then pro-
vided both the Fab and the form to the treating physician. 
HICKEY ET AL. 591 
DIGOXIN-SPECIFIC FAB. EXPANDED DATA ON SAFETY 
Treating physicians completed the remainder of the form and 
sent it to the Project Office at Burroughs We 11 come Co., 
which maintained the study data. The portion of the form 
completed by clinicians requested patient demographic data, 
a brief medical history including allergies or asthma, as-
sumed cause of the digitalis toxicity, pretreatment labora-
tory values, signs of digitalis toxicity before Fab treatment, 
other treatments administered before Fab, amount of Fab 
administered and outcome of treatment including adverse 
events. A follow-up form was sent directly from the Project 
Office to the reporting physician to obtain information on the 
patient's clinical course during the 3 weeks after treatment. 
Three weeks was the minimal amount of follow-up time 
deemed necessary to monitor any occurrence of Fab-
induced serum sickness. The follow-up form requested in-
formation on any additional posttreatment adverse events 
irrespective of attribution, including recrudescent digitalis 
toxicity and complications with readministration of digitalis. 
At no time were patient names requested. Treating physi-
cians used their own clinical judgment in managing the 
episode of toxicity. The study protocol did not require 
assessments, interventions or laboratory tests but did ask 
clinicians to report the results of such evaluations, if per-
formed. An observational design was selected so that find-
ings would reflect the general clinical experience with Fab. 
The study was overseen by an independent medical advisory 
panel (C.D.F, C.H.K., H.C.S., T.W.S.) that met regularly 
throughout the study to evaluate the design and progress and 
review the findings. 
In some cases evaluation of patient response to treatment 
and cause of adverse events was especially difficult because 
of the severity of the underlying disease, the limited ability 
to determine whether the patient had true digitalis intoxica-
tion (and thus if Fab could have been expected to have an 
effect) and the lack of a suitable control group for compari-
son. Because the cases were complex, all adverse events and 
reports of nonresponse to treatment were evaluated by a 
single cardiologist who was not a member of the advisory 
panel but who served as an independent medical reviewer 
(M.A.H.l. The reviewer systematically assessed the likeli-
hood that an event was attributable to Fab or a result of 
underlying disease or recrudescent toxicity. Cases of nonre-
sponse were reviewed to determine the possible reasons for 
nonresponse. 
Statistical analysis. Confidence intervals for proportions 
were based on the binomial distribution. Univariate statisti-
cal tests on categorical variables included Fisher's exact test 
and the chi-square test for homogeneity. Multivariate logis-
tic regression analysis was performed with the LOG 1ST 
procedure in SAS (17). 
Results 
Enrollment and patient follow-up. A total of 717 adult 
treatments occurring at 487 hospitals were reported to the 
Project Office. Ninety-one percent of the hospitals were 
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Figure 1. Distribution of age of 717 patients by gender (N = 717). 
Dotted bars = women; solid bars = men. Age not specified: 14 
patients (7 women, 7 men); gender not specified: 2 patients (68 and 
81 years); age and gender not specified: 2 patients. 
university affiliated or were tertiary care facilities. Reports 
on the treatment of 28 children were also received. Data on 
these cases were analyzed separately and will be presented 
in a subsequent report. Follow-up forms were received for 
75% of the 676 adults alive at the time the initial form was 
completed. With one exception, all patients were treated for 
only one episode of toxicity. On the basis of sales data, 
amount of Fab stocked by each hospital and the distribution 
of doses administered to patients in this study, an estimated 
5,000 treatments occurred in the United States during the 2 
year term of the study. Therefore, data were reported on 
approximately 15% of all treatments. 
Patient demographics. Of the 717 patients, 430 (60%) 
were women and 283 (40%) were men. The gender of four 
patients was not reported. More than 60% of patients were 
>70 years old (Fig. 1). The median age was 75 years for 
women and 72 years for men. 
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Adult clinical history: impaired renal function. Most pa-
tients (94%) were reported as having an underlying cardio-
vascular disorder. Approximately 32% of all patients had 
severe impairment of renal function, 35% moderate impair-
ment and 8% mild impairment as determined by estimating 
the rate of creatinine clearance in ml/min per 70 kg based on 
age, gender and serum creatinine (18). We defined severe 
renal impairment as a clearance of <25 mllmin per 70 kg, 
moderate impairment ~25 to <50 (women) or ~25 to <60 
(men) and mild impairment ~50 to <75 (women) or ~60 to 
<85 (men). An additional 39 patients for whom the estimated 
creatinine clearance could not be determined but whose 
serum creatinine exceeded 1.5 mgldl were categorized as 
having mild (n = 7), moderate (n = 22) or severe (n = 10) 
renal impairment based on reported clinical information. 
History of allergy or asthma. This was specifically re-
quested on the data form and 82 patients (11 %) were 
reported to have such a history. Patients were allergic to 
antibiotics (n = 35), other drugs (n = 19), foods (n = 3) and 
pollens (n = 2); the specific allergy was not reported for 12 
patients. Eleven patients had a history of asthma. None of 
these 82 patients underwent skin testing (intradermal or 
prick) for Fab sensitivity before treatment. Twenty of the 
remaining 635 patients underwent skin testing before treat-
ment with Fab: of these, 19 patients had no reaction to the 
skin test and 1 patient had an equivocal reaction but no sign 
of an allergic response after treatment with Fab. 
Type of dosing resulting in digitalis intoxication. The dose 
of digoxin administered and serum digoxin concentrations 
are summarized in Table 1. Most patients were on mainte-
nance therapy and were taking conventional doses of digox-
in. Severe renal impairment was more common in patients 
with toxicity during maintenance therapy (40%) or after 
loading doses (38%) than in patients with a single overdose 
(7%). Single overdoses included both accidental and suicidal 
Table 1. Amount of Digoxin Ingested and Serum Digoxin Level by Type of Dosing in 717 Patients' 
Amount Ingested (mg/day or mg) Percentiles of Serum Concentrationt (ng/ml) Percentiles of 
the Distribution the Distribution 
No. With No. With 
Amount Amount 
Type of Dosing No. % Specified 10% Median 90% Specified 10% Median 90% 
Maintenance 508 71 419 0.13 0.25 0.25 492 2.5* 4.2 8 
Loading or in·hospital 58 8 50 0.25 0.81 1.98 53 2.2§ 4.6 9 
treatment 
Single ingestion 85 12 55 1.0 5.0 17.7 83 411 9 24 
(patients with heart 
disease) 
Single ingestion 35 5 22 3.2 10.0 25.0 32 5 11 25 
(patients without 
heart disease) 
Unknown or 31 4 26 3.7 7 18 
unspecified 
'Values for three patients with digitoxin intoxication are excluded; tvalues exceeding 5 ng/ml were rounded to the nearest integer; *27 values <2.0 ng/ml; 
§one value <2.0 ng/ml; Iitwo values <2.0 ng/ml. 
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Figure 2. Selected signs of digitalis intoxication in 717 
patients by presence or absence of heart disease. Open 
bars = 36 patients without heart disease: closed bars = 
678 patients with heart disease: presence or absence of 
heart disease could not be determined for 3 patients. 
50% 
o 
ingestions. As expected. these patients ingested greater 
amounts of digoxin and had appreciably higher serum dig-
oxin concentrations than did patients who became intoxi-
cated after therapeutic administrations. The time interval 
between ingestion of digoxin and sample collection for assay 
was not requested on data forms. 
Signs of digitalis intoxication before treatment with Fab. 
Physicians were asked to indicate which of \0 specific signs 
of digitalis intoxication were present before treatment with 
Fab. Of these specific manifestations, ventricular fibrillation 
was present in \0%, asystole in 9%, ventricular tachycardia 
in 20%, hyperkalemia in 26%, third degree atrioventricular 
(A V) block in 27%, ventricular extrasystoles in 29%, second 
degree AV block in 14%. supraventricular arrhythmia in 
27%, first degree AV block in 17% and nausea or vomiting in 
48%. It was not always clear whether the hyperkalemia 
resulted from renal impairment. severe digitalis intoxication 
(resulting in substantial inhibition of sodium and potassium 
transport), or both. 
Alternatively, patients were categorized by the presence 
of ventricular ectopic activity, bradycardia or block. or both, 
or extracardiac signs only before treatment (Fig. 2). The 
relative proportions of patients presenting with ventricular 
ectopic activity, bradycardia or A V block and extracardiac 
symptoms of digitalis intoxication differed according to the 
presence or absence of underlying heart disease. Specifi-
cally, patients with heart disease were more likely to have 
ectopic activity with or without a conduction defect than 
were those without heart disease. However, the effect of 
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variables such as other treatments received before Fab on 
these relations is unknown. 
Treatments received before Fab. Because Fab is indicated 
for potentially life-threatening digitalis intoxication and was 
a new therapeutic entity, many other treatments were likely 
to have been attempted before Fab. Ten percent of patients 
had received cardiopulmonary resuscitation before treat-
ment with Fab. 9% direct current cardioversion, 18% ven-
tricular pacing, 25% antiarrhythmic drugs. 1% a beta-
adrenergic blocking agent and 4% a calcium channel 
blocking agent. A total of 340 patients (47%) were reported 
to have received Fab before any other treatment to reverse 
the toxic episode. The proportion of patients who received 
Fab before other therapies was similar for those whose 
toxicity resulted from long-term digoxin therapy and for 
those with a single overdose. 
Dose of Fab administered and response to treatment. 
Doses administered to adult patients ranged from 8 mg « 1 
vial) to 1.600 mg (40 vials). The median dose was 120 mg 
(three vials) and the most frequently administered dose was 
80 mg (two vials). A total of 357 (50%) of the 717 patients 
were reported to have had a complete reversal of the signs of 
toxicity, 172 (24%) had partial reversal and 89 (12%) had no 
response to treatment. The response was not reported or 
reported as uncertain for 99 patients (14%) (Fig. 3). The 
relation between adequacy of the dose of Fab administered 
and the patient's response to treatment was evaluated. An 
estimated .. adequate" dose was calculated based on patient 
body weight and serum digoxin or digitoxin level for patients 
594 HICKEY ET AL. 
DIGOXIN-SPECIFIC FAB, EXPANDED DATA ON SAFETY 
lACC Vol. 17, No.3 
March 1, 1991:590-8 
TREATING PHYSICIANS 
Response to Treatment 
with Fab 
Complete n = 357 
Partial n = 172 
Evaluation of Digitalis 
Toxicity as Cause of Unresolved. 
Rlst·Treatment Abnormalities 
Not Applicable 
< Yes NolU ncertain n = 137 n = 35 
MEDICAL REVIEWER 
Rlssible Reasons Why 
No Response Observed 
Not Applicable 
Not Evaluated 
Not Evaluated 
Figure 3. Response of 717 patients to 
treatment with Fab. 
~~:~ unexplained treatment failure inadequate dose of Fab No "_89~Y. n = 14 n = 2 n = I n = 5 patient moribund prior to Fab questionable diagnosis of digitalis toxicity case not evaluable 
NoIU ncertain n = 75 
with toxicity from therapeutic administrations and on the 
amount ingested for those patients with toxicity resulting 
from a single overdose. Forty-seven patients received <50% 
of an adequate dose, 69 received 50% to <75%, 155 received 
75% to <100% and 359 received ~100% of the estimated 
neutralizing dose. No clear relation between initial response 
to treatment and percent of the estimated adequate dose 
actually administered was observed. 
Nonresponse to F ab was reported for 14% of the patients 
with toxicity after maintenance dosing, 20% of patients with 
toxicity after loading doses or in-hospital treatment and 15% 
of patients with heart disease who ingested a single over-
dose. In contrast, none of the patients without heart disease 
who ingested a single overdose were nonresponders to Fab. 
The differences in response by dose category approached 
but did not achieve statistical significance, perhaps because 
of the small number of patients in the group without heart 
disease. Several patients had relatively mild signs of toxicity 
or relatively low serum concentrations of digoxin. However, 
response to Fab did not appear to vary by severity of 
presenting signs even when persons with serum digoxin 
concentrations <3.0 ng/ml were excluded from the analysis. 
For those patients whose response was reported as less 
than complete, the form requested that physicians report 
whether residual abnormalities were still believed to be due 
to digitalis intoxication (Fig. 3). The abnormalities for 20% of 
the patients with a partial response and for 16% of those with 
no response were still believed to be due to digitalis intoxi-
cation. The independent cardiologist concluded that four 
cases represented possible treatment failure. These four 
cases, as reported by treating clinicians, are described in the 
Appendix. 
Adverse events. The clinical course of 215 patients in-
volved at least one reported adverse medical event at some 
time after treatment with Fab. Only 52 patients (7%) had an 
event considered possibly or probably related to the admin-
istration of Fab. A total of 171 patients (24%) were reported 
to have died; none of the deaths were attributed to Fab. 
Eighty-six deaths (50%) occurred within 2 days and 142 
(83%) occurred within 3 weeks after Fab treatment. Events 
Evaluations Not Presented 
coded as possibly or probably related to Fab by either the 
reporting clinician or the medical reviewer were categorized 
into four groups: allergic type responses, possible recrudes-
cent digitalis toxicity, complications associated with read-
ministration of digitalis after Fab treatment and other events 
(Tables 2 to 4). 
Allergic responses (Table 2). Six possible or probable 
allergic reactions were reported; four occurred on the day of 
treatment and one each occurred 11 and 16 days after 
treatment. Three patients developed a pruritic rash on the 
day of treatment, and one of these also had facial swelling 
and flushing. The three other possible or probable allergic 
reactions are less clearly attributable to Fab and included 
urticaria, thrombocytopenia and an episode of shaking and 
chills without fever. Two other events, fever and an episode 
of wheezing and dyspnea, may have represented allergic 
responses; however, the course of these events appeared to 
be more consistent with underlying clinical problems than 
with an allergic reaction. These two cases were not included 
in the estimated incidence of allergic response. 
Thus, 0.8% of patients (6 of 717, 95% confidence interval 
0.3% to 1.8%) developed allergic responses during treatment 
with Fab. The likelihood of allergic response was distinctly 
greater in patients with a history of allergy or asthma. Of the 
six allergic responses, four (5%, 95% confidence interval 
1.3% to 12%) occurred among the 82 patients with a history 
of allergy or asthma. Three (9%, 95% confidence interval 
1.8% to 23%) were in the subgroup of 35 patients with a 
history of allergy to antibiotics; all three developed a pruritic 
rash. The incidence of allergic response in the 635 patients 
without a history of allergy or asthma was 0.3% (95% 
confidence interval 0.04% to 1.1%). 
Recrudescent toxicity (Table 3). Twenty (2.8%, 95% con-
fidence interval, 1.7% to 4.3%) of the 717 patients experi-
enced an event reported by the treating physician or retro-
spectively evaluated by the medical reviewer as 
recrudescent toxicity. Sixteen of the 20 cases recurred 
within 3 days of the initial treatment with Fab, including 5 
that recurred within 12 h. The remaining four patients had 
recurrence of toxicity from 4 to 11 days after treatment. Five 
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of the six patients given additional Fab for recurrent toxicity 
had complete reversal of the recurrent toxicity and the sixth 
had a partial response to the second administration of Fab. 
Recrndescent toxicity was more frequent among persons 
receiving less than the estimated adequate dose of Fab. Of 
the 47 patients who received <50% of the estimated dose, 4 
(8.5%) had recurrence of toxicity compared with 4 (5.8%) of 
the 69 who received 50% to <75%, 4 (2.6%) of the 155 who 
received 75% to < 100% and 8 (2.2%) of the 359 who received 
a full neutralizing dose. 
Inadequacy of the initial dose was the only factor asso-
ciated with recrndescent digitalis toxicity in a multivariate 
logistic regression analysis that also included variables rep-
resenting renal function and response to Fab treatment. The 
risk of recrudescent toxicity in persons receiving <50% of 
the estimated adequate dose was 5.8 (95% confidence inter-
val 3.7 to 9.0) times greater than that of persons receiving 
100% of the adequate dose. The relative risk for patients 
receiving 50% to <75% was 3.2 (95% confidence interval 2.0 
to 5.0) and that of patients receiving 75% to <100% of the 
adequate dose was 1.8 (95% confidence interval 1.1 to 2.8) 
times that of patients receiving 100% of the estimated 
adequate dose. 
Complications with readministration of digitalis. One hun-
dred twenty-nine patients resumed digitalis therapy a median 
of 7 days (25% within 4 days, 75% within 13 days) after 
treatment with Fab. Two patients developed a rapid ventric-
ular response to atrial fibrillation after Fab treatment. The 
ventricular response was not controlled by digoxin adminis-
tered 1 day (one patient) and 4 days (one patient) after 
treatment with Fab. 
Other adverse events (Table 4). Twenty-six patients ex-
perienced an event other than an allergic response, recru-
descent digitalis toxicity or complication of readministration 
of digitalis that either the reporting physician or medical 
reviewer considered possibly or probably related to treat-
ment with Fab. Fourteen patients had an adverse cardiovas-
cular event that the medical reviewer judged was due to 
incomplete response to Fab treatment (n = 4), the patients' 
moribund status before treatment with death occurring 
shortly after treatment (n = 2) and withdrawal of inotropic 
effect of digitalis (n = 5). Events experienced by the latter 
group included pulmonary edema, hypotension with de-
creasing cardiac output, congestive heart failure, congestive 
heart failure with left ventricular dilation and electromechan-
ical dissociation. A possible relation between Fab treatment 
and premature ventricular complexes in another patient 
could not be ruled out. The medical reviewer judged the 
events experienced by the two remaining patients as unre-
lated to Fab. Noncardiovascular adverse events were infre-
quent and generally attributable to underlying disease or 
concomitant therapy. 
Retreatment with Fab. Only one patient was reported to 
have been treated with Fab for more than one episode of 
digitalis toxicity. A 42 year old woman was treated twice 
approximately 2 months apart. In both instances toxicity 
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Table 3. Summary of 20 Cases of Recrudescent Digitalis Intoxication 
Estimated 
Assessments of Manifes-
tations as Signs of Recru-
Adequate Posttreatment descent Toxicity' 
Pretreatment Dose Interval 
Age (yr)1 Renal Administered Before Response to Initial Reporting Medical 
Manifestation Gender Impairment (%) Recurrence Fab Treatment Physician Reviewer 
Atrioventricular block 
(n = 5) 30/F No 13 8h Complete Yes Probable 
36/F No 47 7h Partial Yes Unlikely 
78/F No 60 IOh Partial Yes Probable 
81IF Moderate 81 7 days Not specified Yes Possible 
911F Moderate >100 2 days Complete Yes Possible 
Ventricular arrhythmia 
(n = 7) 44/F Mild >100 2 days Complete Yes Unlikely 
47/F Severe >100 15 h Partial Yes Unlikely 
56/F No 60 3 days Partial Yes Possible 
64/F Severe 66 2 days Complete Yes Possible 
64/F Severe >100 20 h Partial Yes Unlikely 
67/F Severe 100 5 days Complete No Possible 
78/F Moderate >100 3 days Complete Yes Possible 
Asystole 
(n = 3) 711F Severe 100 11 days Complete Yes Possible 
74/F Severe 78 I day Complete Yes Possible 
79/M Severe 43 12 h Partial No Possible 
Not specified 
(n = 5) 79/F Severe 85 1 h Partial Yes Unlikelyt 
811M Unknown >100 4 days Complete Yes Possible 
831M Unknown 84 2.5 days Partial Yes Possible 
841M Severe 71 I day Complete Yes Possible 
87/F Severe 46 2 days Partial Yes Possible 
'Reporting physicians coded either yes or no; the medical reviewer coded unlikely, possible or probable; tconsidered to be a single episode of toxicity rather 
than recrudescent toxicity based on partial response and short interval before reported recrudescence of toxicity. 
Table 4. "Other" Adverse Events in 26 Patients 
Cardiovascular disorders 
Atrioventricular block 
Ventricular arrhythmia 
Asystole 
Congestive heart failure 
Urologic disorders 
Renal failure (resolved with i heart rate) 
Acute tubular necrosis (history of urogenital cancer, nephrectomy) 
Hematuria 
Gastrointestinal disorders 
Increasing hepatic enzymes, jaundice (postoperative patient) 
Diarrhea (history of Crohn's disease) 
Nausea 
Metabolic disorders 
Hyperkalemia (2 patients treated concurrently with potassium) 
Hypokalemia 
Hypoglycemia 
No. of 
Patients 
14 
4 
5 
4 
3 
6 
3 
Number of Events 
Attributed to Fab 
Treatment' 
Reporting Medical 
Physician Reviewer 
0 
3 
2 
4 4 
0 
0 
0 
0 1 
0 
0 
2 
'Attribution of possible or probable by either reporting clinician or medical reviewer. Events attributed to Fab 
by the medical reviewer include those resulting from incomplete response and withdrawal of inotropic effect of 
digitalis. 
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resulted from suicidal overdose attempts, the first with 
7.5 mg digoxin and the second with 6.25 mg digoxin. The 
patient received 320 mg Fab in the first treatment and 360 mg 
in the second and responded to both treatments. No adverse 
events were reported in association with either treatment. 
Discussion 
Comparison with results of multicenter clinical trial. This 
observational study extends the reported clinical experience 
with heterologous, digoxin-specific antibody fragments of 
ovine origin in persons with potentially life-threatening dig-
italis intoxication. Unlike the multicenter trial (14-16) that 
preceded this study, in which there were many younger 
patients with suicidal ingestions of digitalis, the majority of 
patients in this study were > 70 years old, had underlying 
heart disease and developed digitalis intoxication during 
long-term maintenance therapy. However, overall favorable 
response to Fab and a low incidence of treatment-related 
adverse events were found in both studies. In the present 
study, complete or partial reversal of toxicity was reported 
for 75% of all patients or 86% of those for whom a response 
was specified. In the multicenter trial (16) a complete reso-
lution of signs and symptoms of toxicity was observed in 119 
(80%) and improvement in 14 (10%). Seven percent of our 
patients were reported to have experienced an adverse event 
compared with 9% of the 150 patients treated in the multi-
center trial. 
Response to Fab treatment. When presumed digitalis tox-
icity did not respond to treatment, incorrect diagnosis of 
digitalis toxicity, inadequate doses of Fab and presence of a 
moribund state before treatment may have contributed to 
nonresponse. Attempts to discern a dose-related lack of 
response were unsuccessful, perhaps owing to variability in 
physicians' assessments of response and in the accuracy of 
diagnoses and estimated adequate doses of Fab based on 
non steady state serum digoxin concentrations. Reported 
response was found to vary by presence or absence of heart 
disease. Percent response was highest for those patients 
without a history of heart disease who ingested a single 
overdose of digoxin. This finding could have resulted from 
increased accuracy of the diagnosis of digitalis intoxication 
or the absence of confounding cardiac abnormalities caused 
by underlying disease in these patients. 
Recrudescent digitalis intoxication. Approximately 3% of 
patients developed recrudescent digitalis intoxication. 
Eighty percent of the cases of recrudescent toxicity occurred 
within 3 days of the initial treatment with Fab; however, one 
case occurred as late as 11 days after treatment with Fab. 
Inadequacy of the initial dose of Fab appeared to be predic-
tive of recrudescent toxicity, whereas completeness of re-
sponse to the initial dose and pretreatment renal function did 
not. The risk of recrudescence was six times more likely in 
patients given less than one half of the calculated dose than 
in patients given a full neutralizing dose. Regardless of dose, 
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recurrence of toxicity was infrequent; even among those 
patients at highest risk, <9% had recrudescence. 
Allergic reactions. At the conclusion of the multicenter 
trial of Fab (16), no allergic reactions to Fab had been noted; 
therefore, the incidence of allergic reactions in previously 
unexposed patients could not be estimated. From this study 
possible or probable allergic reactions to ovine Fab can be 
estimated to occur in about 1 of 120 patients treated. The 
incidence of allergic reactions was higher in patients with a 
history of allergy to antibiotics; 1 in 12 of these patients 
experienced an allergic reaction. However, all allergic re-
sponses were effectively managed with conventional ther-
apy. This study could not assess the likelihood of an allergic 
response with subsequent Fab treatment; only one retreat-
ment for a separate episode of toxicity was reported. Further 
evaluation of the immunogenic potential of Fab in retreat-
ment is needed. In this regard it is of interest that none of the 
600 patients who were administered heterologous monoclo-
nal murine antimyosin Fab fragments developed an allergic 
reaction or a significant increase in antimouse antibody titer 
after injection (19). 
Study limitations. As with any observational study of this 
nature, there are many limitations that may affect interpre-
tation of these data. First, the nature and frequency of 
adverse events occurring in patients treated with Fab could 
not be assessed relative to another similar but untreated 
group of patients. All cases of nonresponse and adverse 
events were reviewed by an independent cardiologist to 
provide additional insight into the cause of events; neverthe-
less, retrospective review, especially with limited data, can 
be inconclusive. Second, an estimated 15% of all treatments 
occurring in the United States within the first 2 years of 
availability were reported. It is possible that some adverse 
events related to Fab treatment occur very rarely and 
therefore were not observed in this study. However, our 
sample size of 717 adults is sufficient to conclude that such 
events, if they occur, occur no more frequently than in 4 of 
1,000 patients treated. Third, reporting bias could have 
occurred. Some treatments for suicidal ingestion may have 
been withheld for reasons of patient confidentiality. Also, it 
is possible that physicians underreported cases of digitalis 
toxicity occurring after therapeutic, in-hospital administra-
tion of digoxin. We cannot determine the extent to which 
such bias might have occurred or the possible effects on 
these findings. The reporting of all treatments was strongly 
encouraged but no reimbursement was provided. However, 
we did not observe any differences by cause of the toxic 
episode in the reported response to treatment or the fre-
quency of allergic responses, recrudescent toxicity or other 
adverse events of possible attribution to Fab. In addition, 
the geographic distribution and size of hospitals reporting 
treatment were comparable with those of hospitals receiving 
Fab but electing not to report treatment. Bias could have 
occurred in the reporting of follow-up data; however, per-
cent follow-up of eligible cases was high (76%) and willing-
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ness to report follow-up data did not appear to vary by cause 
of the toxic episode or initial response to treatment. 
Conclusions. Despite the potential shortcomings inherent 
in studies of this type, this data base represents the largest 
single source of information on human exposure to poly-
clonal Fab fragments. Many patients in this study were of 
advanced age with deteriorated clinical status both from 
life-threatening digitalis intoxication and underlying heart 
disease. The results from this observational study and those 
from the multicenter clinical trial suggest that treatment with 
digoxin-specific antibody fragments provides substantial 
benefit even in such cases and is associated with a low 
incidence of treatment-related adverse events. In contrast to 
previous trials in which no allergic responses and few cases 
of recrudescent toxicity were seen, allergic response was 
reported for 0.8% and recrudescent toxicity for 2.8% of the 
717 patients in this study. A history of allergy to antibiotics 
and insufficient initial doses of Fab contributed to the 
occurrence of allergic responses and recrudescent toxicity, 
respectively. 
We express our gratitude to the many pharmacists. physicians and nurses 
whose participation made this study possible. 
Appendix 
Case 1. A 73 year old, 86 kg Asian man with congestive heart 
failure, chronic obstructive pulmonary disease and bronchial asthma 
who was receiving quinidine sulfate, 200 mg four times a day, and 
digoxin, 0.125 mglday, presented with nausea, vomiting, hyperkale-
mia, first degree A V block and cardiac arrest according to the 
clinician's report. He became comatose before Fab treatment. 
His serum digoxin level was 4.4 ng/ml, serum creatinine 3.6 mg/dl, 
blood urea nitrogen (BUN) was 30 mg/dl and serum potassium 
5.3 mEqlIiter. The patient received antiarrhythmic drugs and under-
went cardiac pacing before administration of 160 mg of Fab. Nine 
hours after treatment, the patient was in complete heart block with 
a junctional rhythm of 52 beats/min and was still deeply comatose. 
The patient was maintained on a pacemaker. Serum creatinine was 
3.7 mgldl. No follow-up data were reported. 
Case 2. An 84 year old, 73 kg white woman with congestive heart 
failure became digoxin intoxicated as a result of self-misdosing. 
Nausea and vomiting, bradycardia (heart rate 17 to 30 beats/min), 
third degree A V block, ventricular extrasystoles and ventricular 
fibrillation were reported to have occurred before treatment. Serum 
digoxin concentration was 9.8 nglml, blood urea nitrogen 23 mgldl, 
serum creatinine 1.6 mg/dl and serum potassium 5.3 mEq/liter. The 
patient received 240 mg Fab but continued to have severe bradyar-
rhythmias requiring pacing. The time course before assessment of 
response and placement of the pacemaker was not specified. No 
follow-up data were reported. 
Case 3. A 71 year old, 46 kg white woman with congestive heart 
failure, chronic obstructive pulmonary disease, and recent myocar-
dial infarction became digitalis intoxicated while receiving 
0.25 mglday digoxin. Before treatment she had had nausea, vomit-
ing, supraventricular arrhythmias, first and second degree heart 
block and ventricular extrasystoles. Serum digoxin concentration 
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was 4.5 nglml. blood urea nitrogen 40 mgldl, serum creatinine 
2.0 mgldl and serum potassium 3.8 mEq/liter. She received 80 mg 
Fab with no response. The signs of toxicity resolved approximately 
5 days later. 
Case 4. An 86 year old, 55 kg white woman with a history of 
seizure disorder and unspecified heart disease was taking mainte-
nance digoxin; however, toxicity resulted from an apparent single 
overdose of unknown quantity. The patient had also taken an 
overdose of phenobarbital and an elevated serum phenytoin level of 
25 mgldl was reported. She had had supraventricular arrhythmias, 
third degree A V block and ventricular extrasystoles before treatment. 
Her serum digoxin level was 7 nglml. blood urea nitrogen 10 mgldl, 
serum creatinine 0.7 mgldl and serum potassium 4.7 mEqlIiter. She was 
administered antiarrhythmic drugs before receiving 280 mg Fab. The 
third degree A V block persisted for 36 h after treatment, then resolved 
to first degree A V block. 
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